SCHEMBL5454024

SCHEMBL5454024

C=CCOc1cccc2cnccc12

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.57
HTT P42858 1/20 0.45
SETDB1 Q15047 1/20 0.45
CYP3A4 P08684 2/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPKAPK2 P49137 1/20 0.45
CYP2A6 P11509 1/20 0.44
IMPDH2 P12268 2/20 0.43
NR3C1 P04150 2/20 0.42
CACNA2D1 P54289 4/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7991108 0.84 KCNA3 (0.57) KCNA3HTTCYP3A4LMNACYP1A2
SCHEMBL94801 0.82 KCNA3 (0.61) KCNA3HTTCYP3A4LMNACYP1A2
SCHEMBL4371294 0.80 HPGD (0.56) KCNA3SETDB1CYP3A4CYP1A2CYP2C19
SCHEMBL96699 0.79 KCNA3 (0.67) KCNA3HTTCYP3A4LMNACYP1A2
SCHEMBL14251166 0.79 KCNA3 (0.61) KCNA3HTTCYP3A4LMNACYP1A2
SCHEMBL11144866 0.79 KCNA3 (0.61) KCNA3HTTCYP3A4LMNACYP1A2
Water SCHEMBL21694712 0.78 HPGD (0.55) KCNA3SETDB1CYP3A4CYP1A2CYP2C19
Ethylene SCHEMBL3362752 0.78 HPGD (0.55) KCNA3SETDB1CYP3A4CYP1A2CYP2C19
SCHEMBL96203 0.78 KCNA3 (0.69) KCNA3HTTCYP3A4LMNACYP1A2
SCHEMBL96408 0.77 KCNA3 (0.72) KCNA3HTTCYP3A4LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
CN-1608061-A Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2005-04-20 CN disclosed
EP-1451172-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS AstraZeneca AB (SE) 2004-09-01 EP disclosed
WO-2003037887-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010526-A1 Therapeutic isoquinoline compounds HTR1B, HTR1D, HTR1A KCNA3 1248/4885HTT 322/4885SETDB1 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.